Home MarketWockhardt Ltd.

Wockhardt Ltd. Stock Info: As on 2017-09-22 15:59:56

Nse

613.65

-41.65(-6.36%)
Change%
52 Week Range
530.65
22.00
945.00
29.00
Open652.80
Day's Range589.77 - 720.83
Value Traded (in ₹ Cr.) 120.59

Bse

613.55

-41.80(-6.38%)
Change %
52 Week Range
531.50
22.00
945.00
29.00
Open653.00
Day's Range589.82 - 720.89
Value Traded (in ₹ Cr.) 18.99

Stock Exchange

Category No. Of Shares Share %
ForeignPromoters 0.00 0.00%
IndianPromoters 81,985,382.00 74.16%
Mutual Funds/UTI 1,556,766.00 1.41%
FII 5,018,755.00 4.54%
Employee 0.00 0.00%
Public 15,586,686.00 14.10%
Government 0.00 0.00%
Others 4,827,327.00 4.37%
More

Key Statistics

Valuation Measures
Market Cap / Sales Ratio 4.83
Basic EPS (Rs.) 2.97
Cash EPS 12.18
BVPerShare Excl 98.68
Operating Revenue 201.33
PBDITPerShare 16.73
Dividend 0.00
NPPerShare 2.97
Current Ratio 1.52
Quick Ratio 1.10
PriceToBV 9.86
Earnings 0.00
PBDIT Margin 8.31
PBT Margin 0.14
NP Margin 1.47
Return On Assets 0.70
Retention Ratios 0.00
Parameter Mar-16 (₹ Cr.) Yoy%change
Total Income 2,281.05
Total Expenses 2,277.84
EBITDA 184.91
PBT 3.21
PAT 32.79
Net Income 32.79
More
Parameter Mar-16 (₹ Cr.) 6M % change
Total Income 1,177.86
Total Expenses 1,063.80
EBITDA 62.33
PBT 62.12
PAT 96.85
Net Income 0.00
More
Total Assets
Total Assets
Parameter Mar-16 (₹ Cr.) Yoy%change
Total share capital 353.80
Net worth 1,388.98
Investments 297.22
Total Liability 4,641.03
Total debt 1,716.31
Net block 1,973.06
Total Assets 4,641.03
Parameter Mar-16 (₹ Cr.) 6M % change
Total share capital 353.80
Net worth 1,388.98
Investments 297.22
Total Liability 4,641.03
Total debt 1,716.31
Net block 1,973.06
Total Assets 4,641.03
Company Curr Price Prev. Close Change% W's Low/High

Aarti Drugs Ltd.

526.85 535.6 -1.63
526544.45

Abbott India Ltd.

4252.9 4252.25 0.02
40014264

Ajanta Pharma Ltd.

1208.5 1256.6 -3.83
11881265

Albert David Ltd.

287.8 292.5 -1.61
282.5300.9

Alembic Ltd.

40.2 43.1 -6.73
38.1544.7

Alembic Pharmaceuticals Ltd.

489.95 500.35 -2.08
469.85504

Alkem Laboratories Ltd.

1800.95 1801.2 -0.01
17341819
Company Curr Price Prev. Close Change% W's Low/High

Aarey Drugs & Pharmaceuticals Ltd.

103.15 101.05 2.08
90121.9

Aarti Drugs Ltd.

524.5 533.85 -1.75
525540

Aayush Food & Herbs Ltd.

48.55 48.55 0
48.5548.55

Abbott India Ltd.

4164 4269.8 -2.48
40354275

ABL Bio-Technologies Ltd.

0.81 0.78 3.85
0.750.81

Addlife Pharma Ltd.

0.46 0 0
0.460.5

Adinath Bio-Labs Ltd.

0.3 0.31 -3.23
0.30.3
More
Parameter Mar-16(in ₹ Cr.)
Cash from operating activities -363.18
Cash from investing activities -1,015.33
Cash from financing activities 763.89
Net change in cash -614.39

Stock Held By Mutual Fund Schemes

Scheme Holding (%)
HDFC Mid-Cap Opportunities Fund - Regular Plan 0.09%
HDFC Capital Builder Fund - Regular Plan 0.70%
Kotak Equity Arbitrage Fund - Regular Plan 0.14%
Reliance Arbitrage Advantage Fund 0.18%
Edelweiss Arbitrage Fund 0.30%
SBI Arbitrage Opportunities Fund 1.02%

SAIL eyes higher market share on surging steel demand: Chairman

Armed with latest technologies and higher product mix, SAIL aims to tap big into the steel demand in India, which is projected to become the fifth- largest economy this year, its Chairman P K Singh said. Addressing the 45th annual general meeting of the state- owned Steel Authority of India Ltd (SAIL) here, Singh said the steel demand in India will witness a significant growth in future, given the current stage of development in Indian economy. The World Steel Association, in its short range outlook, has forecast 6.1 per cent growth in steel consumption for India in 2017, the SAIL chief added. According to Singh, the domestic steel demand is improving on the back of government policies and developmental goals, and SAIL is expeditiously equipping itself to serve market requirements fully and claim a broader market share. SAIL with newer and better technologies at its disposal aims to leverage potential of growth in steel demand by operating at rated capacities, product differentiation and customer satisfaction, Singh said. The chairman also shared the company's efforts towards product value addition. SAIL has done significant value addition in its product mix, with higher grades of steel... from Rourkela Steel Plant's new plate mill for the oil and gas sector, SAIL HT-600 for the automotive sector and high strength LPG steel grade from Bokaro Steel Plant, etc, Singh said. At Bhilai Steel Plant (BSP), the world's longest single piece rail of 130 metres is being produced and supplies of welded 260 metres rail panels to the Indian Railways are in progress. Besides, a 3 mtpa hot strip mill in Rourkela is slated to be installed by 2018. He further said, World economic recovery is on track... and presents a healthy sign for industrial and manufacturing activities across globe. India is projected to become the world's fifth-largest economy in 2017, surpassing UK and France and the world's third largest economy by 2023, surpassing Japan and Germany. Such kind of growth will definitely create larger steel demand and boost consumption in country, the chairman added. Listing out the achievements of SAIL, Singh said the company since inception has produced 475 million tonnes (mt) of crude steel and partnered in all major national projects requiring steel. The company is also taking initiatives towards remodelling its operations.

22-09-2017 16:49

PNB plans to raise up to Rs 5000 cr from markets

Punjab National Bank today said it plans to raise up to Rs 5,000 crore equity capital from the markets to fund growth. The public sector bank however did not give any indication as to whether it would be raised by diluting government equity or issuing Additional Tier-1 (AT1) bonds. The decision in this regard would be taken in the board meeting on September 27, PNB said in a filing to the stock exchanges. The bank would consider raising common equity Tier capital up to Rs 5,000 crore as per Basel III requirements, it said. PNB had reported over 12 per cent rise in net profit at Rs 343.40 crore for the quarter ended June 30, 2017. Total income of the bank rose to Rs 14,468.14 crore in the said quarter from Rs 13,475.41 crore a year ago. With regard to assets metrics, the bank's gross non- performing assets (NPAs) declined marginally to 13.66 per cent of gross advances as on June 30, 2017 from 13.75 per cent a year ago. Meanwhile, shares of the Bank closed trading at Rs 137.80 apiece, down 2.92 per cent from the previous close on BSE.

22-09-2017 15:47

SBI's new index at LSE to help investors track Indian bonds

State Bank of India, in partnership with FTSE Russell, brought out a new index series at the London Stock Exchange to enable investors and market participants to track Indian bond movement. FTSE Russell is a global data and analytics provider. The FTSE SBI Bond Index Series demonstrates SBI's commitment to play befitting leadership role in development of India's bond market, State Bank of India (SBI) said in a statement. We have teamed up with FTSE Russell to launch the FTSE- SBI Bond Index Series. This index will act as a key benchmark for Indian debt for foreign investors looking to invest in Indian debt market, SBI Chairman Arundhati Bhattacharya said in the statement. It will significantly contribute to development and broadening of the Indian bond market, Bhattacharya hoped. The index series, SBI said, provides the global investor community and other market participants the tools they need to analyse India's bond market. The launch follows the November 2015 visit of Prime Minister Narendra Modi in the UK when a letter of intent was singed between SBI and FTSE to jointly develop the new index tracking Indian fixed income securities. This initiative was also announced as a priority under the India UK Financial Partnership (IUKFP), SBI said further. Today's launch of this innovative index series demonstrates SBI's commitment to play befitting leadership role in development of India's bond market. This index is also an important enabler of India-focused funds and is expected to facilitate investment flows, the bank said. Meanwhile, shares of the Bank closed trading at Rs 261.90 apiece, down 2.46 per cent from the previous close on BSE.

22-09-2017 15:44

Adhunik Industries hits 52 week low on SAT order

Shares of Adhunik Industries plunged 20 per cent, hitting 52-week low, on the Bombay Stock Exchange after the Securities Appellate Tribunal (SAT) directed the market regulator to reverse their decisions all dated August 7, 2017 qua the appellant forthwith. According to data available with exchange, as much as 792 lakh shares changed hands over-the-counter as compared to two week average of 1.54 lakhs. Weighed down by the development, shares of the company declined as much as 20 per cent to hit 52-week low of Rs 83.55 apiece on the Bombay Stock Exchange. The stocks were currently trading at Rs 83.55 against previous close price of Rs 104.40. In a similar fashion, shares of the company were trading 19.98 per cent lower at Rs 79.10 apiece on the National Stock Exchange. Meanwhile, the broader benchmark BSE Sensex was trading at 31,944.47, down 425.57 points, or 1.30 per cent, at 14:45 hours.

22-09-2017 14:57

Dabur India joins hand with Amazon for ayurveda marketplace

Homegrown FMCG major Dabur India today said it has tied up with e-commerce major Amazon for an online ayurveda marketplace which will house all ayurvedic brands and products available in the country. The company, which will also offer consumers an insight into various ayurvedic medicines for treating a variety of ailments, said the idea is to service all health and personal care related needs of patients. The exclusive ayurveda e-marketplace has been hosted by Amazon India and the content is developed by Dabur India, the company said in a statement. Consumers can search basis companies, brands and ailments and will gain access to all ayurveda solutions available in the country today, Dabur India Executive Director Consumer Care Business KK Chutani said. Products of other ayurvedic manufacturing companies like Baba Ramdev-promoted Patanjali and Himalaya would also feature on the marketplace. By providing A+ content for developing this marketplace, Dabur also gains prime visibility on the portal, Chutani said. Meanwhile, shares of the company were trading at Rs 305.70 apiece, down 1.51 per cent from the previous close at 14:50 hours on BSE.

22-09-2017 14:48

Wockhardt Ltd. - Shareholders meeting

Wockhardt Limited has informed the Exchange with copy of minutes of Annual General Meeting held on August 02, 2017

21-Aug-2017 06:17 PM

Wockhardt Ltd. - Minutes Of Annual General Meeting

In furtherance of our intimation dated 2nd August, 2017 with respect to Disclosure of Voting Results at the Annual General Meeting ('AGM') along with the Scrutinizer's Report; and Outcome of AGM, we are pleased to enclose herewith copy of Minutes of AGM.

Kindly take the above information on record.

21-Aug-2017 06:08 PM

Wockhardt gets US FDA nod for Antibiotic Injection

Pharmaceutical and biotechnology major Wockhardt said that it has received approval from the United States Food & Drug Administration (US FDA) for an ANDA for 1gm, and 2gm injections of Oxacillin. Oxacillin is a penicillanase-resistant beta-lactam antibiotic and is used to treat many different infections caused by penicillin-resistant Staphylococcal and other bacterial infections, such as Urinary Tract Infections, Respiratory Tract Infections, Septicemia, Wound Infection, Bacterial meningitis etc, the company said in a filing to the Bombay Stock Exchange. Wockhardt is expected to launch this product in the United States, soon. The product is being manufactured at a contract manufacturing facility, based near Milan, Italy. Meanwhile, shares of the company were trading at Rs 604.20 apiece, up 0.75 per cent from the previous close at 11:46 hours on BSE.

07-Aug-2017 11:39 AM

Wockhardt Ltd. - Press Release

Wockhardt Receives US FDA Approval for Antibiotic Injection


Pharmaceutical and biotechnology major Wockhardt has received approval from the United States Food & Drug Administration (US FDA) for an ANDA for 1gm, and 2gm injections of Oxacillin.

Oxacillin is a penicillanase-resistant beta-lactam antibiotic and is used to treat many different infections caused by penicillin-resistant Staphylococcal and other bacterial infections, such as Urinary Tract Infections, Respiratory Tract Infections, Septicemia, Wound Infection, Bacterial meningitis etc.

Wockhardt is expected to launch this product in the United States, soon. The product is being manufactured at a contract manufacturing facility, based near Milan, Italy.



07-Aug-2017 09:16 AM

Wockhardt Ltd. - Press Release

Wockhardt Limited has informed the Exchange regarding a press release dated August 07, 2017, titled Wockhardt Receives US FDA Approval for Antibiotic Injection.

07-Aug-2017 09:13 AM

Wockhardt Ltd. - Minutes Of Annual General Meeting

In furtherance of our intimation dated 2nd August, 2017 with respect to Disclosure of Voting Results at the Annual General Meeting ('AGM') along with the Scrutinizer's Report; and Outcome of AGM, we are pleased to enclose herewith copy of Minutes of AGM.

Kindly take the above information on record.

21-Aug-2017 06:08 PM

Wockhardt Ltd. - Press Release

Wockhardt Receives US FDA Approval for Antibiotic Injection


Pharmaceutical and biotechnology major Wockhardt has received approval from the United States Food & Drug Administration (US FDA) for an ANDA for 1gm, and 2gm injections of Oxacillin.

Oxacillin is a penicillanase-resistant beta-lactam antibiotic and is used to treat many different infections caused by penicillin-resistant Staphylococcal and other bacterial infections, such as Urinary Tract Infections, Respiratory Tract Infections, Septicemia, Wound Infection, Bacterial meningitis etc.

Wockhardt is expected to launch this product in the United States, soon. The product is being manufactured at a contract manufacturing facility, based near Milan, Italy.



07-Aug-2017 09:16 AM

Wockhardt Ltd. - Outcome of AGM

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 ('Listing Regulations') read with Para A of Part A of Schedule III of the Listing Regulations, we wish to enclose herewith gist of proceedings of the 18th Annual General Meeting of the Company held today.

02-Aug-2017 04:33 PM

Corporate Details

About Management

YEAR EVENTS 2000 - Wockhardt has launched cardiac drug enalapril maleate in the US through its marketing joint venture with Sidmak Laboratories. - Pharmaceutical major Wockhardt Ltd has set up a corporate training centre with modern and state-of-the-art facility under one roof at Aurangabad. 2001 - Wockhardt Hospitals Ltd, the wholly owned subsidiary of Wockhardt Ltd, will set up two cardiac hospitals in Mumbai and Bangalore. - The Company has terminated its three-year old marketing alliance with Sidmak Laboratories, one of the top ten generic pharma companies in the US. - Pharma major Wockhardt Ltd. has entered into a strategic alliance with a Japanese firm Eisai Company Ltd. to manufacture and market a neurology drug -- Methycobal. - Wockhardt Hospitals Ltd, the wholly owned subsidiary of pharmaceutical major Wockhardt Ltd, has tied up with four international health insurance companies to offer medical cover to non-resident Indians. - AGM JUNE 8 2001 Wockhardt has launched an innovative and attractive employee stock option scheme, ESOP. - Wockhardt Ltd has introduced an employee stock option (ESOP) scheme for over 175 employees in the senior and middle management levels with about 2,00,000 shares being allotted. 2002 -The Hari L Mundra has joined Wockhardt as vice-chairman. Mundra will spearhead the company's domestic operations which account for 70 per cent of its turnover. - Wockhardt Ltd has appointed Mr. Lalit Kumar as Executive Director on its Corporate Board. Mr. Kumar will spearhead Wockhardt's International Business covering bulk drug operations and formulations export, as well as ANDA research and Intellectual Property Rights. 2003 -Wockhardt restructured its field organization to upgrade its competitiveness and productivity. -Mumbai based wockhardt will hit the domestic market with the first indigenously developed insulin soon, in a move to induce turmoil in the market. -Wockhardt has launched new four speciality hospitals at its Mulund complex in Mumbai. -Maharashtra Government decided to terminate its Joint Venture agreement with Wockhardt for setting up a super speciality hospital. -Wockhardt Limited has acquired CP pharmaceuticals(Holdings) Ltd, along with its subsidiaries. -Wockhardt is strengthening its marketing strategies and distribution system to unveil human insulin in Indian market. -Wockhardt Launched Asia's first human recombinant insulin, making India the first Asian country to develop, manufacture and market the product. -Wockhardt Ltd has received USFDA approval for marketing bethanecol Chloride tablets in the US. -Wockhardt baged USFDA approval for Bethanechol -Baged US approval to sell bethanechol chloride tablets -Wockhardt Ltd has informed that Mr. JS Khorakiwala who has been on the board of the company as Executive Director, has resigned from the directorship with immediate effect. 2004 -Wockhardt Ltd has filed an Investigational New Drug (IND) application for its new drug for respiratory infections, WCK-1152 - Wockhardt Ltd has acquired German pharmaceutical company esparma GmbH for a consideration of $11 million (around Rs 49 crore). -Centre for Drug Evaluation & Research, an arm of the US Food & Drug Administration (US FDA), has approved the sterile injectable facility as well as facilities for sterile bulk drugs (active pharmaceutical ingredient) and formulations spread over three locations in India -Wockhardt gets USFDA nod for 6 manufacturing units 2005 -Launches of India's first automatic insulin delivery device specially designed for the convenience of Indian diabetic patients on February 14, 2005 -Wockhardt forges alliance with Kamineni Group to establish two world-class heart hospitals in the Hyderabad -Wockhardt unveils father`s heart network -Wockhardt receives US FDA approval for marketing cefuroxime axetil in the US market -Wockhardt unveils new generation hepatitis A vaccine -Wockhardt rolls out new Hepatitis A vaccine 2006 -Wockhardt's Waluj plant approved by US FDA 2007 -Wockhardt signs in-licensing pact with Crawford Healthcare of UK. -Wockhardt Ltd has appointed Mr. Rajiv B Gandhi as Director- Finance & Information for a period of five years effective from February 22, 2007, subject to the approval of shareholders. -Wockhardt Ltd has announced US FDA approval for marketing Ketorolac anti-inflammatory injection in the US market, its third US FDA approval in the last ten days. - Wockhardt Ltd on May 03, 2007 has announced the acquisition of Negma Laboratories, the fourth largest independent, integrated pharmaceutical group in France with sales of $ 150 million. The Company has acquired Negma Laboratories in an all-cash deal worth $ 265 million. The transaction is valued at 1.8 times the sales and 9.7 times the EBITDA. 2008 Wockhardt Ltd has unveiled Cetirizine tablets in the US, after having got the regulatory clearance to market different strengths of anti-allergy medicine Cetirizine Hydrochloride. Cetirizine is the generic version of Pfizer's Zyrtec brand and the total market for Cetirizine tablets in the US is $1.4 billion. - Wockhardt Ltd has forayed into a 10- year in-licensing pact with the UK's Sinclair Pharma plc to market dermatology and dental products in India. 2009 -A biotechnology breakthrough in Diabetes Wockhardt launches new insulin (Glaritus) in India. -Harvard Medical School Professor shows connection of Cancer and Heart diseases with Diabetes. -Wockhardt announces its succession plan under the leadership of Chairman Habil Khorakiwala. -Wockhardt launches anti-hypertensive drug Nicardipine injections in USA. -Wockhardt wins Government of India Patent Award. -Wockhardt appoints BDO Haribhakti as auditor. -Wockhardt announces Entacapone patent settlement with Orion Corporation. 2010 -Wockhardt receives US FDA approval for antibacterial Levofloxacin -Wockhardt launches Prostate drug Flomax in the United States on Day-1. -Wockhardt receives US FDA approval for the generic version of Toprol XLr, a cardiac drug. 2011 -Wockhardt launches generic version of Protonixr tablets in the US. -Wockhardt receives US FDA approval for generic version of Effexor XRr capsules. -Wockhardt launches three new products in three weeks, in the United States. -Wockhardt receives tentative US FDA approval for generic version of Patanolr ophthalmic solution. 2012 -Wockhardt launches generic version of anti--ulcer drug Prevacidr. -Wockhardt receives US FDA approval for generic version of Parkinsonism drug Requip XLr. -Wockhardt receives tentative US FDA approval for generic version of anti-psychotic drug Geodonr. -Wockhardt receives US FDA approval for generic version of Parkinson's drug Comtanr. 2013 -Wockhardt receives the 'Best Enterprise' award from the Europe. -Wockhardt launches generic version of anti-convulsant drug Lamictal XR. 2014 -Wockhardt's drug discovery gets a boost with fast track approval by USFDA. 2015 -Wockhardt Receives ANDA Approval for pain medication Oxycodone liquid -Wockhardt receives Qualified Infectious Disease Product (QIDP) designation for its new Drug WCK 4873 from U.S. FDA -US FDA grants breakthrough (QIDP) drug discovery status to the New Antibiotic of Wockhardt 2015 -Wockhardt receives Qualified Infectious Disease Product (QIDP) designation for its new Drug WCK 4873 from U.S. FDA -Wockhardt receives ANDA approval for pain medication Oxycodone liquid -Wockhardt gains over 2% after MHRA completes plant inspection -Wockhardt gets QIDP status for new antibiotic from US FDA.

Registered Office

PO Barotiwala,

01795-664444,,,      01795-664312,

Registrar Details

Link Intime India Pvt. Ltd.